Electrophysiological effects of adipose graft transposition procedure (AGTP) on the post-myocardial infarction scar: A multimodal characterization of arrhythmogenic substrate.
adipose graft transposition procedure
arrhythmic risk
mapping
myocardial infarction
myocardial repair
ventricular tachycardia
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
06
2022
accepted:
23
08
2022
entrez:
7
10
2022
pubmed:
8
10
2022
medline:
8
10
2022
Statut:
epublish
Résumé
To assess the arrhythmic safety profile of the adipose graft transposition procedure (AGTP) and its electrophysiological effects on post-myocardial infarction (MI) scar. Myocardial repair is a promising treatment for patients with MI. The AGTP is a cardiac reparative therapy that reduces infarct size and improves cardiac function. The impact of AGTP on arrhythmogenesis has not been addressed. MI was induced in 20 swine. Contrast-enhanced magnetic resonance (ce-MRI), electrophysiological study (EPS), and left-ventricular endocardial high-density mapping were performed 15 days post-MI. Animals were randomized 1:1 to AGTP or sham-surgery group and monitored with ECG-Holter. Repeat EPS, endocardial mapping, and ce-MRI were performed 30 days post-intervention. Myocardial SERCA2, Connexin-43 (Cx43), Ryanodine receptor-2 (RyR2), and cardiac troponin-I (cTnI) gene and protein expression were evaluated. The AGTP group showed a significant reduction of the total infarct scar, border zone and dense scar mass by ce-MRI ( AGTP is a safe reparative therapy in terms of arrhythmic risk and provides additional protective effect against adverse electrophysiological remodeling in ischemic heart disease.
Sections du résumé
Objective
UNASSIGNED
To assess the arrhythmic safety profile of the adipose graft transposition procedure (AGTP) and its electrophysiological effects on post-myocardial infarction (MI) scar.
Background
UNASSIGNED
Myocardial repair is a promising treatment for patients with MI. The AGTP is a cardiac reparative therapy that reduces infarct size and improves cardiac function. The impact of AGTP on arrhythmogenesis has not been addressed.
Methods
UNASSIGNED
MI was induced in 20 swine. Contrast-enhanced magnetic resonance (ce-MRI), electrophysiological study (EPS), and left-ventricular endocardial high-density mapping were performed 15 days post-MI. Animals were randomized 1:1 to AGTP or sham-surgery group and monitored with ECG-Holter. Repeat EPS, endocardial mapping, and ce-MRI were performed 30 days post-intervention. Myocardial SERCA2, Connexin-43 (Cx43), Ryanodine receptor-2 (RyR2), and cardiac troponin-I (cTnI) gene and protein expression were evaluated.
Results
UNASSIGNED
The AGTP group showed a significant reduction of the total infarct scar, border zone and dense scar mass by ce-MRI (
Conclusion
UNASSIGNED
AGTP is a safe reparative therapy in terms of arrhythmic risk and provides additional protective effect against adverse electrophysiological remodeling in ischemic heart disease.
Identifiants
pubmed: 36204562
doi: 10.3389/fcvm.2022.983001
pmc: PMC9530287
doi:
Types de publication
Journal Article
Langues
eng
Pagination
983001Informations de copyright
Copyright © 2022 Adeliño, Martínez-Falguera, Curiel, Teis, Marsal, Rodríguez-Leor, Prat-Vidal, Fadeuilhe, Aranyó, Revuelta-López, Sarrias, Bazan, Andrés-Cordón, Roura, Villuendas, Lupón, Bayes-Genis, Gálvez-Montón and Bisbal.
Déclaration de conflit d'intérêts
FB served as a consultant for Biosense Webster and Abbott and has received speaker honoraria from Boston Scientific, Biosense Webster, Biotronik, and Abbott. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Cardiovasc Magn Reson. 2020 Mar 12;22(1):19
pubmed: 32160925
J Mol Cell Cardiol. 2016 Feb;91:114-22
pubmed: 26739214
Circulation. 1988 Mar;77(3):589-606
pubmed: 3342490
HeartRhythm Case Rep. 2017 Nov 22;4(2):70-72
pubmed: 29876292
Circ Arrhythm Electrophysiol. 2015 Apr;8(2):390-9
pubmed: 25740836
Med Image Anal. 2016 Aug;32:131-44
pubmed: 27086166
J Mol Cell Cardiol. 2010 Nov;49(5):771-80
pubmed: 20713059
Europace. 2015 Jun;17(6):938-45
pubmed: 25616406
JACC Clin Electrophysiol. 2020 Jul;6(7):799-811
pubmed: 32703562
EBioMedicine. 2016 May;7:248-54
pubmed: 27322478
Eur Heart J. 2020 Jan 1;41(1):12-85
pubmed: 31820000
Circ Arrhythm Electrophysiol. 2013 Jun;6(3):528-37
pubmed: 23685537
Biochim Biophys Acta Biomembr. 2018 Jan;1860(1):40-47
pubmed: 28576298
Cardiovasc Res. 2006 Feb 1;69(2):299-301
pubmed: 16405876
J Vis Exp. 2021 Nov 4;(177):
pubmed: 34806712
J Mol Cell Cardiol. 2015 Apr;81:139-49
pubmed: 25724725
J Am Coll Cardiol. 2005 Aug 16;46(4):667-74
pubmed: 16098433
Comput Biol Med. 2018 Nov 1;102:336-340
pubmed: 30033360
Circ Arrhythm Electrophysiol. 2018 Oct;11(10):e006569
pubmed: 30354406
Cardiovasc Res. 2011 Sep 1;91(4):659-67
pubmed: 21576133
JACC Clin Electrophysiol. 2019 Oct;5(10):1115-1126
pubmed: 31648735
Circ Arrhythm Electrophysiol. 2011 Oct;4(5):674-83
pubmed: 21880674
Pharmacol Ther. 2009 Aug;123(2):151-77
pubmed: 19345240
J Cell Mol Med. 2014 Jul;18(7):1407-16
pubmed: 24780005
Exp Cell Res. 2005 Aug 15;308(2):283-90
pubmed: 15925364
J Am Coll Cardiol. 2012 Oct 23;60(17):1698-706
pubmed: 22999735
J Cardiovasc Pharmacol. 2011 Jun;57(6):630-8
pubmed: 21150449
J Cardiovasc Electrophysiol. 2013 Jul;24(7):813-21
pubmed: 23647964
Int J Cardiol. 2013 Jun 20;166(2):469-74
pubmed: 22137092
BMJ Open. 2017 Aug 04;7(8):e017187
pubmed: 28780562
Arrhythm Electrophysiol Rev. 2019 Mar;8(1):54-59
pubmed: 30918668
Heart Rhythm. 2010 Dec;7(12):1852-9
pubmed: 20833268
Circ Res. 2005 Jul 22;97(2):159-67
pubmed: 15976318
Heart Rhythm. 2016 Feb;13(2):569-83
pubmed: 26410105
Heart Rhythm. 2007 Aug;4(8):1034-45
pubmed: 17675078
Circulation. 2019 Oct 22;140(17):1383-1397
pubmed: 31533463